Figure 3
![Figure 3. Survival rates. Compared with MDS/MPN-U, patients with aCML showed a significant inferior OS (12.4 months, 95% CI [9.0-16.1] vs 21.8 months, 95% CI [17.6-28.8]) and ACL-free survival (11.2 months, 95% CI [7.0-13.5] vs 18.9 months, 95% CI [12.3-26.3]).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/123/17/10.1182_blood-2014-02-553800/4/2645f3.jpeg?Expires=1736040050&Signature=Hr-B598Me1gdxUbYZM-pS40ec4WdQ6a~eyF9RRUNVJUmNOv1l3XIM1yw5TKlbe3HMfJV1Sp5DWDdzI9wF8dTfuAKl9OX4vnmLglmGB9YFJGtPOWJTs71a8cYZD4kQHi4TJHvBhwOp~fy9cI2q2LpbL6ljFyIXDwnYs~NEkB0--R9cIdEN8B4~9iCiYZMQga8CFYmK8I3d2tM76FNJJCp0LnbA2x9JGVVbV8HkYv7x-6ryWGC6Mngmh1984J5sK0PlTB9JsNWXHdk1aTMiTY5mHU6PSv~dcEE0muzAVrU3c6qjdNvKcvlfDCcm1qV2inNkY2EyyHhkzYBO0zVOGaVEg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Survival rates. Compared with MDS/MPN-U, patients with aCML showed a significant inferior OS (12.4 months, 95% CI [9.0-16.1] vs 21.8 months, 95% CI [17.6-28.8]) and ACL-free survival (11.2 months, 95% CI [7.0-13.5] vs 18.9 months, 95% CI [12.3-26.3]).
